# Immune Design

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/immune-design

- Industry: Pharmaceuticals
- Headquarters: Seattle, US
- Website: www.immunedesign.com
- Total disclosed funding: $90M
- Latest round: Series C (Oct 30, 2013)
- Investors on record: 7

## About

Founded in 2008 and based in Washington, US, Immune Design Corp. is a biotechnology company that focuses on developing vaccines and immunotherapies for infectious diseases and cancer. The company offers G100, an intratumoral immune activation designed to leverage endogenous antigens and create a systemic anti-tumor immune response from a local injection, and NY-ESO-1, a tumor antigen for the treatment of synovial and MRCL sarcoma.

## Funding rounds

- Series C, Oct 30, 2013, $48M — Alta Partners, Versant Ventures, The Column Group, OUP (Osage University Partners), Topspin Partners, ProQuest Investments, Sanofi Ventures
- Series B, Oct 3, 2011, $11M — Alta Partners, Versant Ventures, The Column Group, OUP (Osage University Partners), ProQuest Investments
- Series B, Jul 26, 2010, $13M — Alta Partners, Versant Ventures, The Column Group, ProQuest Investments
- Series A, Jun 23, 2008, $18M — Alta Partners, Versant Ventures, The Column Group

## Investors

- Alta Partners (https://capitalatlas.ai/funds/alta-partners) — Series A, Series B, Series C
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B, Series C
- The Column Group (https://capitalatlas.ai/funds/the-column-group) — Series A, Series B, Series C
- ProQuest Investments (https://capitalatlas.ai/funds/proquest-investments) — Series B, Series C
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series B, Series C
- Topspin Partners (https://capitalatlas.ai/funds/topspin-partners) — Series C
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series C